APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease
Thomas F. Tropea,Sharon X. Xie,Jacqueline Rick,Lana M. Chahine,Nabila Dahodwala,Jimit Doshi,Christos Davatzikos,Leslie M. Shaw,Vivianna M. Van Deerlin,John Q. Trojanowski,Daniel Weintraub,Daniel Weintraub,Alice Chen-Plotkin +12 more
TL;DR: The objective of this study was to find baseline predictors of cognitive decline in longitudinally followed, nondemented Parkinson's disease patients.
read more
Abstract: BACKGROUND People with PD are at high risk of developing cognitive impairment and dementia. Cross-sectional studies have identified candidate biomarkers associated with cognitive decline. However, longitudinal studies on this topic are rarer, and few have investigated the use of biomarker panels encompassing multiple modalities. The objective of this study was to find baseline predictors of cognitive decline in longitudinally followed, nondemented Parkinson's disease patients. METHODS We performed a prospective cohort study of 100 PD patients with a median disease duration of 6.4 years. All participants were nondemented at baseline. We examined 16 baseline biomarkers from clinical, genetic, biochemical, and MRI-based imaging modalities for their association with longitudinal cognitive decline for up to 8 years. We investigated biomarkers individually, as well as in a multivariate linear mixed-effects model encompassing multimodal biomarkers, with change in the Mattis Dementia Rating Scale-2 over time as the primary outcome. Annual consensus process-derived cognitive diagnosis was used for Cox proportional hazards modeling of risk for cognitive decline. RESULTS In multivariate analysis, the presence of the APOE E4 allele, thought disorder, and an Alzheimer's disease pattern of brain atrophy (spatial pattern of abnormality for recognition of early Alzheimer's disease index) best predicted cognitive decline, with APOE E4 genotype exerting the greatest effect. The presence of the APOE E4 allele was associated with a 3.5 times higher risk of worsening cognitive diagnosis over time (HR, 3.53; 95% CI, 1.52-8.24; P < 0.05). The APOE genotype effect was not specific to any Mattis Dementia Rating Scale-2 domain. CONCLUSIONS Our results confirm the importance of Alzheimer's disease biomarkers as risk factors for cognitive decline in established Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
TL;DR: Increasing evidence suggests that the effect of APOE*ε4 on AD risk is exerted through inhibition of amyloid-β (Aβ) clearance and promotion of Aβ aggregation, although the relevance of this observation to AD pathogenesis requires further investigation.
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
TL;DR: Both DLB and PDD show heterogeneous pathology and neurochemistry, suggesting that they share important common underlying molecular pathogenesis with AD and other proteinopathies, and there remains a pressing need to differentiate them more clearly.
253
APOE genotype regulates pathology and disease progression in synucleinopathy
Albert A. Davis,Casey E. Inman,Zachary M. Wargel,Umber Dube,Brittany M. Freeberg,Alexander Galluppi,Jessica N. Haines,Dhruva Dhavale,Rebecca L. Miller,Fahim A. Choudhury,Patrick Sullivan,Carlos Cruchaga,Joel S. Perlmutter,Jason D. Ulrich,Bruno A. Benitez,Paul T. Kotzbauer,David M. Holtzman +16 more
TL;DR: It is demonstrated that APOE genotype directly regulates α-synuclein pathology independent of its established effects on Aβ and tau, corroborate the finding that APoe ε4 exacerbates pathology, and suggest thatAPOE ε2 may protect against αSyn aggregation and neurodegeneration in synucleinopathies.
152
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid.
Na Zhao,Olivia N. Attrebi,Yingxue Ren,Wenhui Qiao,Berkiye Sonustun,Yuka A. Martens,Axel D. Meneses,Fuyao Li,Francis Shue,Jiaying Zheng,Alexandra J. Van Ingelgom,Mary D. Davis,Aishe Kurti,Joshua Knight,Cynthia Linares,Yixing Chen,Marion Delenclos,Chia Chen Liu,John D. Fryer,Yan W. Asmann,Pamela J. McLean,Dennis W. Dickson,Owen A. Ross,Guojun Bu +23 more
TL;DR: A pathogenic role of APOE4 is demonstrated in exacerbating α-synuclein pathology independent of amyloid, providing mechanistic insights into how APOE2 or APOE3 increases the risk of LBD.
127
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases
TL;DR: It is proposed that Alzheimer's disease copathology is one of several likely pathological contributors to clinical heterogeneity of Lewy body disorders, and that such pathology can be assessed in vivo.
100
References
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
TL;DR: The pathological findings in 100 patients diagnosed prospectively by a group of consultant neurologists as having idiopathic Parkinson's disease are reported, and these observations call into question current concepts of Parkinson's Disease as a single distinct morbid entity.
10.5K
Random-effects models for longitudinal data
Nan M. Laird,James H. Ware +1 more
TL;DR: In this article, a unified approach to fitting two-stage random-effects models, based on a combination of empirical Bayes and maximum likelihood estimation of model parameters and using the EM algorithm, is discussed.
9.2K
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*
Arthur J. Atkinson,Wayne A. Colburn,Victor G. DeGruttola,David L. DeMets,Gregory J. Downing,Daniel F. Hoth,John A. Oates,Carl C. Peck,Robert T. Schooley,Bert A. Spilker,Janet Woodcock,Scott L. Zeger +11 more
TL;DR: Biomarker measurements provide an avenue for researchers to gain a mechanistic understanding of the differences in clinical response that may be influenced by uncontrolled variables (for example, drug metabolism).
6.5K
Cognitive Profiles of Patients with Mild Cognitive Impairment or Dementia in Alzheimer's or Parkinson's Disease
TL;DR: In advanced stages of both diseases, the pattern of functional deficits associated with parietal and temporal lobe functions (attention, visuoconstruction and language) is similar, however, specific differences, already present in the early stage (recognition errors in AD, associated with mediobasal temporal lobe functioning, and depressed mood in PDD), are also observed in the late stage.
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Lindsay A. Farrer,L. Adrienne Cupples,Jonathan L. Haines,Bradley T. Hyman,Walter A. Kukull,Richard Mayeux,Richard H. Myers,Margaret A. Pericak-Vance,Neil Risch,Cornelia M. van Duijn +9 more
TL;DR: The APOE∈4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women.
4.3K
Related Papers (5)
[...]
Ian G. McKeith,Bradley F. Boeve,Dennis W. Dickson,Glenda M. Halliday,John-Paul Taylor,Daniel Weintraub,Dag Aarsland,Dag Aarsland,James E. Galvin,Johannes Attems,Johannes Attems,Clive Ballard,Clive Ballard,Ashley Bayston,Ashley Bayston,Thomas G. Beach,Thomas G. Beach,Frédéric Blanc,Nicolaas Bohnen,Nicolaas Bohnen,Nicolaas Bohnen,Laura Bonanni,Laura Bonanni,Jose Bras,Jose Bras,Patrik Brundin,Patrik Brundin,David J. Burn,David J. Burn,Alice Chen-Plotkin,John E. Duda,Omar M. A. El-Agnaf,Howard Feldman,Tanis J. Ferman,Dominic Ffytche,Hiroshige Fujishiro,Douglas Galasko,Jennifer G. Goldman,Stephen N. Gomperts,Neill R. Graff-Radford,Lawrence S. Honig,Lawrence S. Honig,Alex Iranzo,Alex Iranzo,Alex Iranzo,Kejal Kantarci,Daniel I. Kaufer,Walter Kukull,Virginia M.Y. Lee,James B. Leverenz,James B. Leverenz,Simon J.G. Lewis,Carol F. Lippa,Carol F. Lippa,Angela Lunde,M Masellis,M Masellis,M Masellis,Eliezer Masliah,Pamela J. McLean,Brit Mollenhauer,Brit Mollenhauer,Thomas J. Montine,Thomas J. Montine,Emilio Moreno,Emilio Moreno,Emilio Moreno,Etsuro Mori,Etsuro Mori,Etsuro Mori,Melissa E. Murray,John T. O'Brien,John T. O'Brien,Sotoshi Orimo,Sotoshi Orimo,Ronald B. Postuma,Ronald B. Postuma,Shankar Ramaswamy,Shankar Ramaswamy,Owen A. Ross,David P. Salmon,David P. Salmon,Andrew B. Singleton,Andrew B. Singleton,Angela Taylor,Angela Taylor,Alan Thomas,Pietro Tiraboschi,Jon B. Toledo,John Q. Trojanowski,Debby W. Tsuang,Zuzana Walker,Zuzana Walker,Masahito Yamada,Masahito Yamada,Kenji Kosaka +95 more
Debby W. Tsuang,James B. Leverenz,Oscar L. Lopez,Ronald L. Hamilton,David A. Bennett,Julie A. Schneider,Aron S. Buchman,Eric B. Larson,Eric B. Larson,Paul K. Crane,Jeffrey Kaye,Patricia L. Kramer,Randy Woltjer,John Q. Trojanowski,Daniel Weintraub,Daniel Weintraub,Alice Chen-Plotkin,David J. Irwin,Jacqueline Rick,Gerard D. Schellenberg,G. Stennis Watson,Walter A. Kukull,Peter T. Nelson,Gregory A. Jicha,Janna H. Neltner,Doug R. Galasko,Eliezer Masliah,Joseph F. Quinn,Kathryn A. Chung,Dora Yearout,Ignacio F. Mata,Jia Y. Wan,Karen L. Edwards,Thomas J. Montine,Cyrus P. Zabetian +34 more
Murat Emre,Dag Aarsland,Dag Aarsland,Richard G. Brown,David J. Burn,Charles Duyckaerts,Yoshikino Mizuno,Gerald A. Broe,Jeffrey L. Cummings,Dennis W. Dickson,Serge Gauthier,Jennifer G. Goldman,Christopher G. Goetz,Arnos Korczyn,Andrew J. Lees,Richard Levy,Irene Litvan,Ian G. McKeith,Warren Olanow,Werner Poewe,Niall Quinn,Christina Sampaio,Eduardo Tolosa,Bruno Dubois +23 more